Manufacturer record
Cureza Healthcare Pvt. Ltd: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
10 batches manufactured by Cureza Healthcare Pvt. Ltd (Madhya Pradesh) were declared Not of Standard Quality between November 2023 and September 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: CHPLT1346, Telmisartan Tablets IP 40 mg (exp Jan 2028). SDTL, Agartala, Tripura (state lab) found it not of standard quality: The sample does not conform to standard quality in respect to the test for ?Dissolution & Assay? performed. Listed in the September 2026 alert.
Records by type
10 records linked to Cureza Healthcare Pvt. Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Telmisartan Tablets IP 40 mg | Batch CHPLT1346Mfg Feb 2026 · Exp Jan 2028 | The sample does not conform to standard quality in respect to the test for ?Dissolution & Assay? performed.Assay | SDTL, Agartala, TripuraState lab | Sep 2026 |
| Co-trimoxaole Tablets IP | Batch CHPLT1004Mfg Dec 2025 · Exp Nov 2027 | The Sample does not Comply for Description as-- uneven light Brown coloured Spots are observed all over the Surface of Almost all the Tablets.Description | FDAL, M. S Chhatrapatri Sambhajinagar, F.D.A Mahrasthra StateState lab | Sep 2026 |
| Calcium and Vitamin D3 Tablets IP (NIL) | Batch CH26T309Mfg Jun 2026 · Exp Nov 2027 | Dissolution Test (Three out of six units even at Stage I less than Q-25 i.e 45%)Dissolution | SDTL, PunjabState lab | Aug 2026 |
| Calcium and Vitamin D3 Tablets IP | Batch CH26T364Mfg Jun 2026 · Exp Nov 2027 | Uniformity of WeightUniformity of weight/content | SDTL, PunjabState lab | Aug 2026 |
| Glimepiride Tablets IP 2mg | Batch CHPLT1027Mfg Dec 2025 · Exp Nov 2027 | The Sample does not Comply with IP Requirements for the Dissolution Test.Dissolution | FDAL, Chhatrapati SambhajinagarState lab | Jul 2026 |
| Calcium and Vitamin D3 Tablets IP | Batch CH26T203Mfg May 2026 · Exp Oct 2027 | Dissolution:-(Calcium) Does not complies with IP limit as 3 out of 6 tablets are less than Q-25% Also some tablets can't even dissolve completely within the prescribed time limit.Dissolution | Govt Analyst PunjabState lab | Jul 2026 |
| Calcium and Vitamin D3 Tablets IP(Calse-D3) | Batch CHPLT562Mfg Dec 2024 · Exp May 2026 | Dissolution and AssayAssay | CDL, KolkataCDSCO lab | Oct 2025 |
| Calcium and Vitamin D3 Tablets IP (Calse-D3) | Batch CHPLT538Mfg Dec 2024 · Exp May 2026 | Dissolution and AssayAssay | CDL, KolkataCDSCO lab | Oct 2025 |
| Fluconazole Tablets IP 150 mg (Flucse - 150) | Batch CHT23621Mfg Feb 2024 · Exp Jan 2026 | Uniformity of weightUniformity of weight/content | CDTL MumbaiCDSCO lab | Sep 2024 |
| Telmisartan Tablets I.P. 40 mg. (Telmisev- 40) | Batch CHT22352Mfg Dec 2022 · Exp Nov 2024 | DissolutionDissolution | RDTL GuwahatiState lab | Nov 2023 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.